Accès ouvert
2025
article
OpenAlex
Katharine J. Drummond, Sarah Cain, Jordan Jones, Sammy Shaya et autres
Mutant isocitrate dehydrogenase (mIDH) inhibition significantly improves progression-free survival in patients with mIDH WHO grade 2 glioma; however, a large proportion of patients will progress, and mechanisms of adaptation to mIDH inhibition remain poorly understood. Perioperative studies with evaluation of paired pre- …
au, us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
James R. Whittle, Mark Rosenthal, Robert Tobler, Monique Topp et autres
Abstract BACKGROUND IDH mutations cause aberrant accumulation of (R)-2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis through abnormal hypermethylation of histones and DNA as well as suppression of normal cellular differentiation. IDH inhibition significantly improves progression free survival in patients with IDH mutant …
au
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Sarah A Cain, Monique Topp, Mark Rosenthal, Robert Tobler et autres
This is a single arm, open label perioperative trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with safusidenib following biopsy, and prior to surgical resection in patients with IDH1 mutated glioma who have not received radiation therapy or chemotherapy. Fifteen …
au, us, gb, tw
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
Caitlin Murphy, Violet Mukaro, Robert Tobler, Rebecca Asher et autres
BACKGROUND: Magnetic resonance imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki-67 proliferation index. Whether MRI accuracy varies by genomic signatures is unknown. We …
au
(code pays fourni par la source)
2016
conference-abstract
OpenAlex
Mustafa Khasraw, Violet Mukaro, Linda West, Karen L. White et autres
e12515 Background: We evaluated the feasibility and the likelihood of achieving high response rates by tailoring neoadjuvant therapy based on individual patient and tumor characteristics. Triple negative (TNBC) and HER2+ pts were treated with chemotherapy. Hormone Receptor (HR)+ HER2- pts were treated …
au, us
(code pays fourni par la source)